Co2 can make one hungry!
http://www.dailymail.co.uk/health/article-5227377/Can-sparkling-water-make-fat.html

Tales of adoption: http://www.suggest.com/lifestyle/1735851/adopted-people-who-tracked-down-their-biological-parents-share-what-happened?utm_campaign=sug-fbk-m-us-e09cbef3&utm_content=1460&utm_source=fbk&utm_term=sug-fbk-m-us-e09cbef3.eshxtlmu#page=1

One is sad since the person was left in a pharmacy.

Nhs retiree gets an experimental cancer drug and after many failed attempts of other chemotgerapy she and her husband are happy she is getting it from Roche. The article said she gets it infused over 4 hours and is monitored over night. She gets Herceptin at the same day.
Source daily mail.

"RO6874281 has previously been taken by a small number of patients in a safety trial. However, this is the first time it has been combined with Herceptin."

The Indian tea diet is how the "human ken doll" lost some weight. He also wishes to have some ribs removed.

http://www.dailymail.co.uk/tvshowbiz/article-5121947/Human-Ken-Doll-Rodrigo-Alves-gets-cosy-Pixee-Fox.html

Girl pretends to be a male to write about sports. When pressed claims to be a pharmacy student.
I wonder why not an athletic trainer or PE student, but instead a pharmacy student?

https://deadspin.com/teen-girl-posed-for-8-years-as-married-man-to-write-abo-1820305588

Do you like what this man says about Fidget Spinners?

http://www.businessinsider.com/do-fidget-spinners-help-with-adhd-focus-children-clinical-psychologist-psychology-toys-2017-5

Breaking FDA ....

Today, Aegerion Pharmaceuticals Inc. agreed to plead guilty in the United States District Court for the District of Massachusetts to two misdemeanor counts of violating the Federal Food, Drug, and Cosmetic Act (FD&C Act) involving the introduction of misbranded Juxtapid (lomitapide) into interstate commerce. In connection with this agreement, the criminal information filed today charged that Juxtapid was misbranded because Aegerion failed to comply with the requirements of the Juxtapid Risk Evaluation and Mitigation Strategy (REMS) program and because the drug’s labeling lacked adequate directions for all of Juxtapid’s intended uses. This agreement resolves a criminal investigation in which the U.S. Food and Drug Administration’s Office of Criminal Investigations played an important role.

Aegerion and one of its senior vice presidents, Charles M. Gerrits, PharmD, Ph.D also agreed to enter into a consent decree of permanent injunction with the United States. The consent decree includes a comprehensive compliance program and legal tools for the FDA to ensure that the defendants comply with the law, subject to judicial oversight. The FDA’s Center for Drug Evaluation and Research was instrumental in crafting the compliance obligations agreed to in the consent decree.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm577101.htm